IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.419
NA - Nord America 1.683
EU - Europa 1.317
SA - Sud America 669
AF - Africa 41
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.603
SG - Singapore 986
CN - Cina 729
BR - Brasile 566
RO - Romania 339
HK - Hong Kong 298
SE - Svezia 257
IT - Italia 185
VN - Vietnam 176
DE - Germania 144
RU - Federazione Russa 123
GB - Regno Unito 66
IN - India 55
AR - Argentina 53
FI - Finlandia 52
CA - Canada 36
AT - Austria 34
MX - Messico 33
ID - Indonesia 32
PL - Polonia 27
JP - Giappone 25
BD - Bangladesh 24
NL - Olanda 19
ZA - Sudafrica 19
IQ - Iraq 17
TR - Turchia 17
EC - Ecuador 16
FR - Francia 15
IE - Irlanda 14
CO - Colombia 12
ES - Italia 12
LT - Lituania 10
PK - Pakistan 10
AE - Emirati Arabi Uniti 8
NP - Nepal 7
SA - Arabia Saudita 7
CZ - Repubblica Ceca 6
BE - Belgio 5
MA - Marocco 5
PY - Paraguay 5
UY - Uruguay 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
IL - Israele 4
PH - Filippine 4
TN - Tunisia 4
UZ - Uzbekistan 4
AU - Australia 3
BB - Barbados 3
CI - Costa d'Avorio 3
CL - Cile 3
DZ - Algeria 3
OM - Oman 3
PE - Perù 3
UA - Ucraina 3
BH - Bahrain 2
EU - Europa 2
GE - Georgia 2
IR - Iran 2
NG - Nigeria 2
SC - Seychelles 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
GA - Gabon 1
HN - Honduras 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
MD - Moldavia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SR - Suriname 1
SV - El Salvador 1
Totale 6.135
Salva come PNG Salva come JPEG
Città #
Singapore 479
Dallas 335
Hong Kong 297
Ashburn 190
Shanghai 157
Hefei 140
New York 138
Beijing 127
Lawrence 95
Princeton 95
Los Angeles 65
Ho Chi Minh City 64
Milan 55
Munich 53
Moscow 52
São Paulo 46
Boardman 44
Nuremberg 40
Hanoi 39
Helsinki 33
Denver 29
Warsaw 26
Tokyo 25
Orem 20
Chennai 19
Brooklyn 18
Guangzhou 18
Vienna 18
Santa Clara 17
London 15
Stockholm 15
Atlanta 14
Dublin 14
Houston 14
Poplar 14
Montreal 13
Curitiba 12
Falkenstein 12
Rio de Janeiro 12
Turku 12
Washington 12
Brasília 11
Johannesburg 11
Manchester 11
Phoenix 11
Rome 11
Seattle 11
Shenzhen 11
Toronto 11
Amsterdam 10
Da Nang 10
Mexico City 10
Ankara 9
Guayaquil 8
Porto Alegre 8
Pune 8
Querétaro 8
Sorocaba 8
Belo Horizonte 7
Biên Hòa 7
Boston 7
Chicago 7
Council Bluffs 6
Goiânia 6
Quanzhou 6
Salvador 6
Baghdad 5
Brussels 5
Buenos Aires 5
Campinas 5
Columbus 5
Frankfurt am Main 5
Jakarta 5
Lappeenranta 5
Monza 5
New Delhi 5
Saint Louis 5
San Francisco 5
Santos 5
São Bernardo do Campo 5
The Dalles 5
Vittoria 5
Catanduva 4
Caxias do Sul 4
Cesano Boscone 4
Charlotte 4
Durban 4
Ha Long 4
Haiphong 4
Hangzhou 4
Honolulu 4
Itajaí 4
Joinville 4
Monsummano Terme 4
Montevideo 4
Mumbai 4
Pelotas 4
Pouso Alegre 4
Quezon City 4
Quito 4
Totale 3.264
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 225
Monkeypox in a patient with undifferentiated connective tissue disease 216
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 132
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 109
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 95
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 78
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 74
Achieving virological control in pan-resistant HIV-1 infection: A case series 73
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 71
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 71
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 70
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 68
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 67
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 66
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 65
Bictegravir 65
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 65
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 62
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 60
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 59
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 58
Darunavir for the treatment of HIV infection 57
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 57
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 57
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 55
Disseminated Mycobacterium chimaera infection favoring the development of Kaposi’s sarcoma: a case report 53
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 53
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 53
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 53
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 52
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 52
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 51
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 51
Inflammation burden score in multidrug-resistant HIV-1 infection 51
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 51
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 51
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 51
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 51
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 50
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 49
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 49
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 49
Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 48
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 48
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 48
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 48
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 47
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 47
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 47
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 46
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 46
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 46
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 46
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 45
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 45
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 45
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 45
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 44
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 44
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 43
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 43
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 42
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 42
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 41
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 40
Immune recovery and T cell subset analysis during effective treatment with maraviroc 40
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 40
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 40
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 40
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 38
An evaluation of cabotegravir for HIV treatment and prevention 38
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 38
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 38
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 37
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 37
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 37
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 37
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 36
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 36
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 36
Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk 35
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 35
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 35
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 35
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 35
Influence of gender in predicting CCR5 coreceptor usage 35
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 34
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels 34
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 34
Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy 34
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 34
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 34
FAILURE TO DARUNAVIR/RITONAVIR CAN EITHER INCREASE OR DECREASE TIPRANAVIR/RITONAVIR GENOTYPIC RESISTANCE SCORE IN HIGHLY TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS 34
LONG TERM CD4 RECOVERY IN FULLY SUPPRESSED SUBJECTS TREATED WITH FIRST LINE HAART IS INFLUENCED BY TIME TO REACH UNDETECTABILITY 34
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 34
Impact of analytical treatment interruption on burden and diversification of hiv peripheral reservoir: A pilot study 33
Is shorter duration of antibiotic treatment feasible in patients with cardiac implantable electronic device infections undergoing device removal? A propensity-adjusted analysis of a 10-year retrospective cohort 33
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 32
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. 32
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis 32
Totale 5.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.142
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202131 0 0 0 0 0 10 1 17 2 0 1 0
2021/202278 0 0 0 18 9 9 2 13 7 4 9 7
2022/2023494 206 103 28 4 8 42 43 36 19 2 1 2
2023/2024463 11 18 81 31 49 121 6 43 1 4 27 71
2024/20252.159 194 25 42 64 89 164 661 167 250 132 114 257
2025/20263.078 523 497 480 903 538 137 0 0 0 0 0 0
Totale 6.364